Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211809
Status:
TERMINATED
Last Update Posted:
2017-03-09
First Post:
2005-09-13
Brief Title:
CBT as an Adjunct to SRIs in the Treatment of BDD
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
A Controlled Trial of Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder
Status:
TERMINATED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
low enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy CBT as an adjunct to serotonin reuptake inhibitor SRI pharmacotherapy in body dysmorphic disorder BDD This study assesses the efficacy of CBT in comparison to relaxation and stress management training RSMT an active control treatment
Detailed Description:
In total 20 BDD patients aged 16 through 65 will participate To be eligible they must meet DSM-IV criteria for BDD have a score of 20 or greater on the BDD modification of the Yale Brown Obsessive-Compulsive Scale BDD-YBOCS and be on a stable therapeutic does of an SRI at least 12 weeks on the SRI with 8 weeks at a therapeutic dose acceptable medications therapeutic daily doses are citalopram 40mg clomipramine 150mg fluoxetine 40mg fluvoxamine 150mg paroxetine 40mg sertraline 50mg and venlafaxine 150mg
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None